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A Ab bs st tr ra ac ct t
Disparities in health outcomes of members of different ancestral or ethnic groups can be
observed in both developed and developing countries and continue to be a global concern.
Genomic medicine can help toward closing this gap by expanding the knowledge on novel alleles
related to disease risk and drug response, their frequencies, and their relation with disease and
drug-response phenotypes, in as many countries and ethnic groups as possible. Without such
knowledge, genomic medicine cannot deliver upon its promise of contributing to health for all.
However, the use of ancestry or ethnicity-related genetic information as a selection criterion for
assigning varying levels of access to health care is condemnable. Translational genomic medicine
will allow for individualized clinical decision making - doing away with the use of race, ethnicity or
ancestry as a proxy.
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The study of ancestry or ethnicity in biological and clinical
sciences continues to raise controversy. In May 2001 the
New England Journal of Medicine (NEJM) published a
landmark study reporting that African-American heart
failure patients with left ventricular dysfunction did not
benefit from the popular angiotensin-converting enzyme
inhibitor drug enalapril, while the same drug reduced the
heart failure hospitalization risk of Caucasian patients by
44% [1]. The NEJM report, which eventually paved the road
for the US Food and Drug Administration (FDA) approval of
BiDil as the first ‘ethnic medicine’ four years later, was
accompanied by two editorials - a rare practice for the NEJM -
one heralding it as ‘great help to physicians in their attempt
to choose the best therapy for heart failure in patients of
different races’ [2], and the other condemning it and
demanding that ‘tax-supported trolling of data bases to find
racial distinctions in human biology must end’ [3]. Large
disparities in health outcomes among socioeconomic and
ethnic groups remain well documented, even in developed
countries, and include drug-response variations due to
genetic polymorphisms with different frequencies in
different population subgroups [4]. Besides, it is unsur-
prising that many drugs work better for Caucasian patients,
given the fact that a clear majority of clinical trial
participants are of European ancestry [5]. Using ancestry or
race/ethnicity as a surrogate biomarker for drug choice at
the level of the individual is acceptable when this is the only
approximation available until better biomarkers for clinical
response are discovered and validated [6]. Using ancestry
for establishing shortcuts in healthcare policy, however, is
not an acceptable practice.
P Pe er rs so on na al li iz ze ed d   m me ed di ic ci in ne e: :   t th he e   i in nd di iv vi id du ua al l   i in n   c co on nt te ex xt t
In biomedical research, using race and ethnicity for strati-
fication and in the reporting of results is often misleading
and may skew scientific outcomes, as outlined by Timothy
Caulfield and colleagues’ well-thought out manuscript in theJanuary 2009 issue of Genome Medicine [7]. In healthcare
policy making, using ‘genetic explanations’ for ancestry-
based provision of services is controversial at the very least.
It is a risky practice, potentially leading down the slippery
slope of denying individuals equal access to prevention and
care based on their ancestral background. At the same time,
the current practice of setting specific criteria for the alloca-
tion of some healthcare resources, as, for example, deter-
mining the eligibility criteria for screening, shows the urgent
need for personalized medicine.
An article comparing the cost-effectiveness of colorectal cancer
screening in different ethnic groups may illustrate these two
aspects [8]. The study examined the cost-effectiveness of
various screening methods for colorectal cancer in different
population subgroups in the USA, using age, gender and
race/ethnicity as classifiers for stratification. The authors
concluded that ‘the cost-effectiveness of a 35-year screening
program in black men beginning at age 45 was … more cost-
effective than screening nonblack women as well as Asian
and Latino men beginning at age 50’. However, even if these
calculations may be correct, they are utterly insufficient in
the era of genomic medicine. More subtle information will
be coming, including genetic biomarkers for cancer
susceptibility, which we should use in the near future in
order not to fall short of due care at the individual level.
Isaac Kohane, in his January 2009 Genome Medicine
commentary [9], asks ‘who are you and whom do you most
resemble?’ He convincingly argues that personalized decision
making requires the combination of information about the
population subgroup a person belongs to, along with
information about the particular individual. Both genomic
and non-genomic information must be taken into account.
When it comes to allocating resources for personalized
medicine, the crucial policy discussion remains that of
‘whose utilities are being maximized, society’s or the
patient’s’ [9]. While the prudent balancing of societal and
individual interests when deciding on policy matters always
requires tough choices, the patient’s ancestry should never
be employed for denying access to health services, just as it
should never be employed for denying access to education
or employment.
T Tr ra an ns sl la at ti io on na al l   g ge en no om mi ic cs s   a an nd d   h hu um ma an n   d di iv ve er rs si it ty y
One of the greatest threats to human integrity and freedom
is the classification of individuals according to their
ancestry/race/ethnicity for assigning civil rights and access
to societal resources. The risk of harm is even larger when
such classifiers are linked to genetic information, given that
the latter is permanent, has inherent privacy risks in the age
of electronic information management, and has implications
for immediate family members [10]. The 20th century has
taught us horrifying lessons on the risks that ethnic
classification poses to human integrity and freedom - lessons
that should not be forgotten when building up for better
health care in the 21st century. Translational genomic
medicine must strive to achieve so that no one can refer to
‘genetic evidence’ for supporting healthcare policy guidelines
that block the access of individuals to medicines or
diagnostic services based on their ancestry. Efforts toward
minimizing healthcare disparities between particular com-
munities are imperative. Such efforts should include
establishing new links between gene alleles, disease risks
and drug-response phenotypes in as many distinct popula-
tions as possible. Moreover, different genes, not just differ-
ent alleles for the same gene, may account for drug
response in different ethnic groups. One example is
azathioprine-mediated myelotoxicity, which is primarily
linked to thiopurine methyltransferase deficiency among
Europeans, Africans and Native Americans but to inosine
triphosphate pyrophosphatase deficiency among Asians
[11]. The translation of such findings into clinical practice
can lead to different diagnostic or treatment strategies in
different countries, based on considerations related to their
major local ethnic populations. But, as Caulfield et al.
implied [7], how effective can such strategies be in countries
with extensive population admixture?
T Tr ra an ns sl la at ti io on na al l   g ge en no om mi ic c   m me ed di ic ci in ne e: :   p pe er rs so on na al li iz ze ed d, ,
m mu ul lt ti ir ra ac ci ia al l
Humans differ in their disease susceptibility and drug
response, with genetic and genomic variations often contri-
buting to such individual differences. Pharmacogenetics,
which plays a key role in personalized medicine, studies the
heritable variations affecting drug response. Currently, it is
the lack of prospective validation studies on genetic markers
for drug safety and efficacy, and not a lack of knowledge
about ethnic variations, that hinders the wider clinical
uptake of pharmacogenetics [12]. If personalized medicine is
to succeed as a research discipline and in its clinical appli-
cation, it must be comprehensive and take into account both
heritable and non-heritable factors affecting drug response.
This has been the message of personalized medicine from its
onset, and it must remain so, putting aside any attempts - be
they driven by sheer commercial interests or cost-effective-
ness considerations - for the establishment of ancestry/
ethnicity as ‘easy shortcuts’.
It is time to recognize that ‘we are all multiracial, related to
each other only to a greater or lesser extent’, quoting
Aravinda Chakravarti, who claims that we must change our
concepts on family, population and race [13]. Consider, for
example, that the 44th President of the United States of
America, portrayed by the media as an African-American,
would be assigned - were he sending his DNA sample to one
of the commercial personal genome providers - as Caucasian
based on his mitochondrial DNA (having a Caucasian
mother), but as an African-American (or rather, of Kenyan
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Genome Medicine 2009, 1 1: :24ancestry) based on his Y chromosome. So, genetically
speaking, is President Barack Obama an African-American
or a Caucasian? Neither. Like all his fellow humans, he is a
member of the human race.
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